GHRP-6 vs Ipamorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicGHRP-6Ipamorelin
What it is

A synthetic hexapeptide amide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), also recorded as hexapeptide-2 and SK&F-110679, according to FDA’s substance registry.3

A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.4

FDA status

Not FDA-approved

No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1

No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.1

Is GHRP-6 FDA-approved?

Not FDA-approved

Unapproved new drug in cited enforcement record2

Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.1,4

Is ipamorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.5,6

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.5,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.1

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study A 2013 pharmacokinetic study in nine healthy men, which measured how quickly GHRP-6 is distributed and cleared, without a comparison group.7

Smaller controlled human trials

  • Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.4
  • Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.4
Records collected

0 ClinicalTrials.gov records and 25 PubMed records collected

2 ClinicalTrials.gov records and 14 PubMed records collected

Area of study

Hormones3

Hormones, Gut and digestion4

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2.1
  2. FDA places GHRP-6 in category 2 under its 503B interim compounding policy, according to its safety-risk page.1
  3. A pharmacokinetic study of GHRP-6 in nine healthy men is published.7
  1. FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.1
  2. FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.4,8
  3. A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  3. 3
    GHRP-6 (hexapeptide-2) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (2013) · PMID 23099431 ↗

    European Journal of Pharmaceutical Sciences · Official source · Source checked November 15, 2026

  8. 8
    Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026